Medivir AB (STO: MVIR), a research-based pharmaceutical company with a focus on oncology, announced on Monday the decision by its board of directors to continue discussions with the US Food and Drug Administration (FDA) to agree on the design of the planned pivotal phase III clinical study of remetinostat for the treatment of early-stage cutaneous T -cell lymphoma (CTCL).
Reportedly, the aim of the continued dialogue with the FDA is to agree upon the design for a phase III study that could, if successfully completed, lead to the approval of the company's most advanced candidate drug within oncology.
According to the company, the start of this study will not be possible earlier than 2019 and not in 2018 as previously communicated.
Medivir firmly believes that remetinostat has an important role in the treatment of various cancers, including early-stage cutaneous T-cell lymphoma, where there is a great unmet medical need. Also, Medivir's commitment to develop remetinostat is based on its significant commercial potential and therefore it is of utmost importance that it designs a phase III study that meets the expectations of the regulatory agencies.
Further discussions with the FDA are needed to ensure that the company can initiate a pivotal study that will allow Medivir to bring this drug through approval and to patients, the company added.
Also, details of the phase III study design will be published at a future date when finalised.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories